{"entity":{"id":"nct07192614","kind":"trial","name":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr","aka":["ACTIVATED-4-PC"],"tldr":"A phase 1/2 trial of AZD6621 in prostate cancer, run by AstraZeneca, now recruiting.","summary":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT07192614 by AstraZeneca, with 52 participants planned, started 2025-09-30 and due to reach its primary completion in 2029-03-29. Interventions recorded: AZD6621. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07192614","url":"https://clinicaltrials.gov/study/NCT07192614"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["azd6621"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07192614","phase":"1/2","setting":"A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer","sponsor":"AstraZeneca","participation":[{"nct":"NCT07192614","source":"https://clinicaltrials.gov/study/NCT07192614","fetchedAt":"2026-10-07T16:55:32.313Z","studySha256":"4d7117d30c88f7e468c59db4b09eafc0dd973a44e15f5f6bc319f0af3fa7f3cb","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-02","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":52,"enrolmentType":"ESTIMATED","siteCount":26,"recruitingSiteCount":15,"countries":["Belgium","Canada","China","Japan","Netherlands","South Korea","Spain","United Kingdom","United States"]}],"started":"2025-09-30","startedType":"actual","enrolled":52,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07192614/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"azd6621","kind":"drug","name":"AZD6621","route":"/drugs/azd6621/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}